Hypertension
Conditions
Brief summary
The purpose of this study is to evaluate pharmacokinetic interactions (Drug-Drug interaction) and safety between BR1015-1 and BR1015-2 in healthy volunteers.
Detailed description
\*Study Objective: After repeated administration of BR1015-1 and BR1015-2 for healthy volunteers, the pharmacokinetic interactions and safety are evaluated. \*Investigational Product (and regimen) 1. BR1015-1: Administration of BR1015-1 60 mg once a day for 5 days 2. BR1015-2: Administration of BR1015-2 1.5 mg once a day for 5 days 3. BR1015-1+BR1015-2: Co-administration of BR1015-1 60 mg and BR1015-2 1.5 mg once a day for 5 days
Interventions
DRUGBR1015-1
\- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
DRUGBR1015-2
\- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
DRUGBR1015-1 + BR1015-2
\- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
One-sequence, 3-period study.
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects are given sufficient explanations about the trial objectives and contents as well as properties of investigational drugs before participating in the trial, and will voluntarily express their consent by signing an IRB-approved written consent to participate in the trial. * Healthy adults aged 19 to 55 years at screening. * The subject's weight is 50 kg or more for males, 45 kg or more for females, and body mass index (BMI) is 18.0 or more but 30.0 kg/m2 or less.
Exclusion criteria
* Those who have history of clinically significant diseases including hypersensitivity reaction, intolerability and anaphylaxis to major ingredients and other ingredients of investigational products. * Those who have history of clinically significant diseases including allergy reaction to Yellow No. 5 (Sunset Yellow FCF). * Those who have a history of clinically significant diseases related to liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncology system, cardiovascular system (including orthostatic hypotension), etc. * Those who have medical history of gastrointestinal system diseases (for example: Crohn's disease, peptic ulcer disease, etc.) and operations that may influence the absorption of investigational drugs. (However, appendectomy, hernia operation, endoscopic polypectomy and hemorrhoids/anal fissure/anal fistula surgeries are excluded.) * Those with abnormal findings from the screening tests (medical interview, vital signs, electrocardiography, physical checkup, blood test, urinalysis, etc.) are judged to have clinical significance. * Those who are positive to HBsAg, HCV Ab, HIV Ab, VDRL tests at screening. * Those with any of the following results at screening: * AST or ALT \> twice the upper limit of normal range * T. bilirubin \> twice the upper limit of normal range * Estimated glomerular filtration rate (e-GFR) \< 60 mL/min/1.73m2 (CKD-EPI method used) * Na \> 150 mEq/L or \<130 mEq/L * K \> 5.5 mEq/L or \<3.0 mEq/L * Those with systolic blood pressure \> 160 mmHg or \< 110 mmHg, or diastolic blood pressure \> 100 mmHg or \< 70 mmHg from vital signs at screening. * Others who are judged to be ineligible to participate in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| [Part A] Cmax,ss of BR1015-1 | 0~24 hour after administration at Day 5. | Pharmacokinetic variables - Maximum (peak) plasma concentration of BR1015-1 at steady state (Cmax,ss). |
| [Part B] Cmax,ss of BR1015-2 | 0~24 hour after administration at Day 5. | Pharmacokinetic variables - Maximum (peak) plasma concentration of BR1015-2 at steady state (Cmax,ss). |
| [Part A] AUCtau of BR1015-1 | 0~24 hour after administration at Day 5. | Pharmacokinetic variables - Area under the plasma drug concentration-time curve to the end of the dosing period in multiple dosing of BR1015-1 at steady state. (AUCtau,ss) |
| [Part B] AUCtau of BR1015-2 | 0~24 hour after administration at Day 5. | Pharmacokinetic variables - Area under the plasma drug concentration-time curve to the end of the dosing period in multiple dosing of BR1015-2 at steady state. (AUCtau,ss) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| [Part A] Tmax of BR1015-1 | 0~24 hour after administration | Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss) |
| [Part B] Tmax of BR1015-2 | 0~24 hour after administration | Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss) |
| [Part A] AUClast of BR1015-1 | 0~48 hour after administration | Area under the plasma drug concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUClast) of BR1015-1 |
| [Part B] t1/2 of BR1015-2 | 0~48 hour after administration | Terminal half-life of BR1015-2 |
| [Part A] t1/2 of BR1015-1 | 0~48 hour after administration | Terminal half-life of BR1015-1 |
| [Part B] AUClast of BR1015-2 | 0~48 hour after administration | Area under the plasma drug concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUClast) of BR1015-2 |
| [Part A] AUCinf of BR1015-1 | 0~48 hour after administration | Area under the plasma drug concentration-time curve over the time interval from 0 extrapolated to infinity of BR1015-1 |
| [Part B] AUCinf of BR1015-2 | 0~48 hour after administration | Area under the plasma drug concentration-time curve over the time interval from 0 extrapolated to infinity of BR1015-2 |
Countries
South Korea
Outcome results
None listed